{"id":"adx415","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD47, ADX415 prevents tumor cells from evading immune surveillance, thereby enhancing the body's immune response against cancer cells.","oneSentence":"ADX415 is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:56.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT00779181","phase":"PHASE2","title":"A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension","status":"COMPLETED","sponsor":"Addrenex Pharmaceuticals, Inc.","startDate":"2008-10","conditions":"Hypertension","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADX415","genericName":"ADX415","companyName":"Addrenex Pharmaceuticals, Inc.","companyId":"addrenex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADX415 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}